文献速递糖尿病肥胖与代谢综合征

每日低剂量阿司匹林与社区居住健康老年人新发2型糖尿病:ASPREE随机安慰剂对照试验的疗效与安全性事后分析

Daily low-dose aspirin and incident type 2 diabetes in community-dwelling healthy older adults: a post-hoc analysis of efficacy and safety in the ASPREE randomised placebo-controlled trial.
PubMed 文献 · Lancet Diabetes Endocrinol · 2023-12-21

ASPREE双盲安慰剂对照试验事后分析纳入16209名无糖尿病社区老年人,随机接受每日100 mg肠溶阿司匹林或安慰剂。中位随访4.7年,阿司匹林组新发2型糖尿病风险降低15%(HR 0.85,95%CI 0.75-0.97),第5年空腹血糖升幅较安慰剂组减缓,但大出血风险增加44%(HR 1.44,95%CI 1.21-1.72)。

要点

  • 阿司匹林组新发2型糖尿病459例,安慰剂组536例,风险降低15%(HR 0.85)。
  • 第5年空腹血糖组间差值估计为-0.048 mmol/L(95%CI -0.079至-0.018)。
  • 阿司匹林组大出血300例(3.7%),安慰剂组210例(2.6%),风险增加44%。

核心结论

  • 阿司匹林治疗降低社区居住老年人2型糖尿病发病率并减缓空腹血糖浓度升高,但增加大出血风险。
  • 鉴于老年人2型糖尿病患病率增加,阿司匹林等抗炎药物预防2型糖尿病或改善血糖水平的潜力需进一步研究并全面评估所有潜在安全性事件。

研究设计与样本

  • ASPREE为双盲、安慰剂对照试验,每日口服低剂量阿司匹林。
  • 研究人群为美国与澳大利亚社区居住的70岁及以上个体(美国少数族裔≥65岁),无心血管疾病、限制独立生活的身体残疾或痴呆。
  • 事后分析排除基线糖尿病或随访期间新发糖尿病数据不完整或缺失的参与者。
  • 参与者按1:1随机分配至口服100 mg每日肠溶阿司匹林或安慰剂。
  • 新发糖尿病定义为自我报告的糖尿病、开始降糖药物治疗,或基线无糖尿病参与者在年度随访时空腹血糖≥7.0 mmol/L。

主要发现

  • 2010年3月10日至2014年12月24日共纳入16209名参与者(阿司匹林组8086名[49.9%],安慰剂组8123名[50.1%])。
  • 中位随访4.7年(IQR 3.6-5.7),记录995例(6.1%个体)新发2型糖尿病(阿司匹林组459例,安慰剂组536例)。
  • 与安慰剂相比,阿司匹林组新发糖尿病风险降低15%(HR 0.85 [95%CI 0.75-0.97];p=0.013)。
  • 与安慰剂相比,阿司匹林组第5年空腹血糖浓度升幅较慢(组间差值估计-0.048 mmol/L [95%CI -0.079至-0.018];p=0.0017)。
  • 大出血(主要胃肠道出血、颅内出血及其他部位临床显著出血)发生于16104名参与者中的510名(3.2%)(阿司匹林组300名[3.7%],安慰剂组210名[2.6%])。

关键数值与推荐

  • 新发糖尿病定义:自我报告的糖尿病、开始降糖药物治疗,或年度随访时空腹血糖≥7.0 mmol/L。
  • 大出血定义:主要胃肠道出血、颅内出血及其他部位临床显著出血。
  • 阿司匹林组新发糖尿病HR 0.85(95%CI 0.75-0.97;p=0.013)。
  • 第5年空腹血糖组间差值估计-0.048 mmol/L(95%CI -0.079至-0.018;p=0.0017)。
  • 阿司匹林组大出血HR 1.44(95%CI 1.21-1.72;p<0.0001)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文为事后分析(post-hoc analysis)。
  • 作者指出阿司匹林等抗炎药物预防2型糖尿病或改善血糖水平的潜力需进一步研究并全面评估所有潜在安全性事件。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Inflammation has been implicated in the pathogenesis of diabetes. This study investigated the randomised treatment effect of low-dose aspirin on incident type 2 diabetes and fasting plasma glucose (FPG) concentrations among older adults. METHODS: ASPREE was a double-blind, placebo-controlled trial of daily oral low-dose aspirin. The study population included community-dwelling individuals aged 70 years or older (≥65 years for US minority ethnic groups) in the USA and Australia who were free of cardiovascular disease, independence-limiting physical disability, or dementia. For the post-hoc analysis, we excluded participants with diabetes at baseline or with incomplete or missing incident diabetes data during follow-up. Participants were randomly assigned 1:1 to oral 100 mg daily enteric-coated aspirin or placebo. Incident diabetes was defined as self-reported diabetes, commencement of glucose-lowering medication, or a FPG concentration of 7·0 mmol/L or more assessed at annual follow-up visits among participants with no diabetes at baseline. We used Cox proportional hazards models and mixed-model repeated measures to assess the effect of aspirin on incident diabetes and FPG concentrations in the intention-to-treat population. We assessed major bleeding in participants who had taken at least one dose of study medication. FINDINGS: Between March 10, 2010, and Dec 24, 2014, a total of 16 209 participants were included (8086 [49·9%] randomly assigned to aspirin and 8123 [50·1%] randomly assigned to placebo). During a median follow-up of 4·7 years (IQR 3·6-5·7), 995 (in 6·1% individuals) incident cases of type 2 diabetes were recorded (459 in the aspirin group and 536 in the placebo group). Compared with placebo, the aspirin group had a 15% reduction in risk of incident diabetes (hazard ratio 0·85 [95% CI 0·75 to 0·97]; p=0·013) and a slower rate of increase in FPG concentration at year 5 (between-group difference estimate -0·048 mmol/L [95% CI -0·079 to -0·018]; p=0·0017). Major bleeding (major gastrointestinal bleeding, intracranial bleeding, and clinically significant bleeding at other sites) occurred in 510 (3·2%) of 16 104 participants (300 [3·7%] in the aspirin group and 210 [2·6%] in the placebo group). Compared with placebo, the aspirin group had a 44% increase in risk of major bleeding (hazard ratio 1·44 [95% CI 1·21 to 1·72]; p<0·0001). INTERPRETATION: Aspirin treatment reduced the incidence of type 2 diabetes and slowed the increase in FPG concentration but increased major bleeding among community-dwelling older adults. Given the increasing prevalence of type 2 diabetes among older adults, the potential for anti-inflammatory agents such as aspirin to prevent type 2 diabetes or improve glucose levels warrants further study with a comprehensive assessment of all potential safety events of interest. FUNDING: US National Institute on Aging, US National Cancer Institute, National Health and Medical Research Council of Australia, Monash University, and the Victorian Cancer Agency.

来源:Lancet Diabetes Endocrinol,查看原文。版权归原作者所有。

引用

  1. Zoungas S, Zhou Z, Owen AJ, et al. Daily low-dose aspirin and incident type 2 diabetes in community-dwelling healthy older adults: a post-hoc analysis of efficacy and safety in the ASPREE randomised placebo-controlled trial. Lancet Diabetes Endocrinol. 2023. PMID: 38142708. doi:10.1016/S2213-8587(23)00327-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。